Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2025Open Access

Analysis of a simple disk diffusion method to evaluate Ceftazidime-avibactam/Aztreonam combination synergism against NDM clinical isolates.

View Full Paper
Ask AI
Bookmark
Share

Authors

RRReena RajanSGSasikala GopinathanARA. V. Raghavendra Rao

Discussion

Loading...

Member takes

Overview

Cross-sectional analysis confirms effectiveness of Ceftazidime-avibactam/Aztreonam synergy against NDM strains, implying potential for treating resistant infections.

Key Points

  • Ceftazidime-avibactam/Aztreonam showed synergy against 63.6% of carbapenem resistant isolates.
  • In total, 25 out of 39 NDM isolates exhibited synergy, indicating promising treatment potential.
  • Analysis utilized the disk diffusion method and involved 62 clinical isolates from 2022 to 2024.
  • Significant differences in inhibition zones reflect the potential advantage of combination therapy.

Cite This Study

Rajan et al. (2025) studied this question.

synapsesocial.com/papers/68e034fdf0e39f13e7fa3676https://doi.org/10.1099/acmi.0.001049.v2
View Full Paper
Ask AI
Bookmark
Share